TNFRSF17 and Miyoshi myopathy: Additionally, a single-center retrospective study (Subramanian et al., 2023), found that among 30 R/R MM patients who progressed after anti-BCMA CAR-T therapy, those receiving Blenrep had an ORR of only 25% and a median PFS of 1.8 months.